AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference

April 2, 2019

BOSTON--(BUSINESS WIRE)--Apr 2, 2019--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK.

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology

Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190402005118/en/

CONTACT: Verastem Oncology:

Rob Gagnon

Chief Financial Officer

+1 781-469-1681

rgagnon@verastem.comInvestors:

Joseph Rayne

Argot Partners

+1 617-340-6075

joseph@argotpartners.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY ONCOLOGY PHARMACEUTICAL FDA

SOURCE: Verastem, Inc.

Copyright Business Wire 2019.

PUB: 04/02/2019 07:00 AM/DISC: 04/02/2019 07:00 AM

http://www.businesswire.com/news/home/20190402005118/en

All contents © copyright 2019 The Associated Press. All rights reserved.